Amitkumar Mehta, MD

Articles by Amitkumar Mehta, MD

Amitkumar Mehta, MD, on Compelling Data From ASH in the Treatment of Lymphoma

February 10th 2022

Amitkumar Mehta, MD, detailed encouraging data presented at the 63rd ASH Annual Meeting for treating mantle cell lymphoma.

$Amitkumar Mehta, MD, discusses overall response rates from the CITADEL-205 study looking at parsaclisib for patients with relapsed/refractory mantle cell lymphoma.$

Amitkumar Mehta, MD, on Results of CITADEL-205 Study Examining Parsaclisib in Relapsed/Refractory MCL

ByAmitkumar Mehta, MD

January 31st 2022

Amitkumar Mehta, MD, discusses overall response rates from the CITADEL-205 study looking at parsaclisib for patients with relapsed/refractory mantle cell lymphoma.

$Amitkumar Mehta, MD, discusses the role of parsaclisib and how it fits into the treatment landscape of relapsed/refractory mantle cell lymphoma.$

Amitkumar Mehta, MD, Discusses the Role of Parsaclisib in Relapsed/Refractory MCL

ByAmitkumar Mehta, MD

January 25th 2022

Amitkumar Mehta, MD, discusses the role of parsaclisib and how it fits into the treatment landscape of relapsed/refractory mantle cell lymphoma.

Amitkumar Mehta on the Immunomodulating Effects of Targeted Therapy for Multiple Myeloma

ByAmitkumar Mehta, MD

December 15th 2016

In this interview we discuss the mechanisms of daratumumab, how it is currently used for the treatment of multiple myeloma, and how it might be used in the future.